Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia

BJU International

Volumn 110, Issue 11, 2012, Pages

  Baade, Peter D ^a,b,c   Youlden, Danny R ^a   Gardiner, Robert A ^d,e,f   Ferguson, Megan ^a   Aitken, Joanne F ^a,b,c   Yaxley, John ^g   Chambers, Suzanne K ^a,c,f,h  

^a CANCER COUNCIL QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f EDITH COWAN UNIVERSITY   (Australia)

^g Brisbane Private Hospital   (Australia)

^h PROSTATE CANCER FOUNDATION OF AUSTRALIA   (Australia)

Author keywords

Clinical factors; Decision making; Demographic factors; Prostate cancer; Treatment

Indexed keywords

ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; AUSTRALIA; BODY MASS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; GLEASON SCORE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT DECISION MAKING; PATIENT TRANSPORT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; TERTIARY HEALTH CARE; UROLOGIST; ADJUVANT THERAPY; BLOOD; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUEENSLAND; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 85032687566     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.011533.x     Document Type: Article

References (28)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. Lyon: IARC, 2010. Available at: http://globocan.iarc.fr/. Accessed 25 May 2011
2. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-48
3. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
4. Carter HB. Management of low (favourable)-risk prostate cancer. BJU Int 2011; 108: 1684-95
5. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010; 183: 2206-12
6. Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, Wallace Kazer M. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev 2010; ( 11 ): CD006590
7. Albertsen PC. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncol 2011; 50 ( Suppl. 1 ): 120-6
8. Cox J, Amling CL. Current decision-making in prostate cancer therapy. Curr Opin Urol 2008; 18: 275-8
9. Zeliadt SB, Ramsey SD, Penson DF et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 2006; 106: 1865-74
10. Branney P, White A, Jain S, Hiley C, Flowers P. Choosing health, choosing treatment: patient choice after diagnosis of localized prostate cancer. Urology 2009; 74: 968-71
11. Singh J, Trabulsi EJ, Gomella LG. The quality-of-life impact of prostate cancer treatments. C urr Urol Rep 2010; 11: 139-46
12. Baade PD, Aitken JF, Ferguson M, Gardiner RA, Chambers SK. Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities. BMC Cancer 2010; 10: 452
13. Medical Outcomes Trust and Quality Metric Incorporated. SF-36: SF-36v2TM Health Survey. ( IQOLA SF36v2 Standard, English (Australia), 7/03). Medical Outcomes Trust and Quality Metric Incorporated, Health Assessment Las: Lincoln, RI, 1992, 2003
14. Thompson SC, Pitts JS, Schwankovsky L. Preferences for involvement in medical decision-making: situational and demographic influences. Patient Educ Couns 1993; 22: 133-40
15. Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia. 2006. Canberra: ABS2008. Report No.: Cat. No. 2033.0.55.001
16. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996; 49: 907-16
17. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23
18. Jang TL, Bekelman JE, Liu Y et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010; 170: 440-50
19. National Health and Medical Research Council and Australian Cancer Network. Clinical Practice Guidelines: evidence-based information and recommendations for the management of localised prostate cancer. A report of the Australian Cancer Network Working Party on Management of Localised Prostate Cancer. Canberra, 2003
20. Harlan LC, Potosky A, Gilliland FD et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001; 93: 1864-71
21. Schymura MJ, Kahn AR, German RR et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 2010; 10: 152
22. Gwede CK, Pow-Sang J, Seigne J et al. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer 2005; 104: 1381-90
23. Sommers BD, Beard CJ, D ' Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113: 2058-67
24. Baade PD, Steginga SK, Pinnock CB, Aitken JF. Communicating prostate cancer risk: what should we be telling our patients? Med J Aust 2005; 182: 472-5
25. Thompson B, Baade P, Coory M, Carriere P, Fritschi L. Patterns of surgical treatment for women diagnosed with early breast cancer in Queensland. Ann Surg Oncol 2008; 15: 443-51
26. Steenland K, Goodman M, Liff J et al. The effect of race and rural residence on prostate cancer treatment choice among men in Georgia. Urology 2011; 77: 581-7
27. Chu DI, Freedland SJ. Prostate cancer. Socioeconomic status and disparities in treatment patterns. Nat Rev Urol 2010; 7: 480-1
28. PHIAC. Quarterly Statistics: Hospital Treatment, General Treatment. Private Health Insurance Administration Council ed., Barton: Australian Government, 2011. Available at: http://www.phiac.gov.au/resources/file/ membershipdata/MC%20Jun11.pdf. Accessed 25 May 2012